[68Ga]Ga-PSMA-11 PET/CT监测转移性前列腺癌治疗反应:是否优于标准随访?
该回顾性研究纳入52例转移性前列腺癌患者,在治疗前及治疗中行[68Ga]Ga-PSMA-11 PET/CT及血清PSA检测,比较基于PSA与基于PET/CT的治疗反应。34例(65.4%)两者一致,18例(34.6%)不一致;影像反应在多数有后续随访的患者中适合指导治疗选择。
要点
- PSA与PET/CT治疗反应在约三分之一转移性前列腺癌患者中不一致。
- 影像反应可基于病灶分析,发现异质性反应、新病灶及需靶向放疗的病灶。
- PET/CT监测反应在多数患者中适合用于治疗决策与选择。
核心结论
- 生化反应与[68Ga]Ga-PSMA-11 PET/CT反应在三分之一转移性前列腺癌患者中不一致。
- PET/CT监测治疗反应在多数患者中适合用于治疗决策和选择。
研究设计与样本
- 回顾性分析纳入52例转移性前列腺癌患者,治疗前及治疗中行[68Ga]Ga-PSMA-11 PET/CT和血清PSA检测。
- 按PSA动态分为改善、稳定和进展,并与治疗前后PET/CT影像变化比较,采用McNemar检验评估一致性。
主要发现
- 34/52例(65.4%)生化与影像反应一致,18/52例(34.6%)不一致。
- 与生化评估相比,PET/CT显示5/52例(9.6%)进展、13/52例(25%)改善或稳定。
- 不一致最常见于生化稳定患者(90.9%),其次为生化进展(33.3%),生化改善者仅8.7%。
- 在30例有较长随访(中位10.3个月,IQR 6.3-18.2)的患者中,22例(73.3%)的影像反应适合选择后续治疗。
临床怎么用
- 对转移性前列腺癌治疗监测,可考虑[68Ga]Ga-PSMA-11 PET/CT补充PSA,尤其生化稳定或进展时。
- 影像反应可指导后续治疗选择,并支持基于病灶的异质性评估和靶向放疗决策。
局限性
- 回顾性分析,样本量52例,部分患者随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of the current study was to assess whether and to what extent monitoring response to treatment using prostate-specific membrane antigen (PSMA)-based positron-emitting tomography/computerized tomography (PET/CT) studies contribute clinically relevant data to routine clinical follow-up during treatment of patients with metastatic prostate cancer (PCa). RESULTS: Fifty-two patients with metastatic PCa who underwent [68Ga]Ga-PSMA-11 PET/CT imaging and serum prostate-specific antigen (PSA) level measurements before and during treatment were investigated. Response was categorized by serum PSA dynamics according to improvement, stable disease, and disease progression and compared to change in imaging findings on pre- and post-treatment PET/CTs. McNemar's test was used to assess agreement between PET/CT- and PSA-based responses to treatment. Thirty-four patients (65.4%) had compatible biochemical- and imaging-based response to treatment. However, the imaging and biochemical responses were discrepant in 18/52 patients (34.6%). PET/CT showed progressive disease in 5/52 patients (9.6%) and improvement/stable disease in 13/52 (25%) compared to biochemical assessment results. Discrepancy between imaging and biochemical response was most prominent in biochemically stable patients (90.9%), followed by patients with biochemical progression (33.3%), and in only few (8.7%) patients with biochemical improvement. The imaging-based response was suitable for choosing subsequent treatment in 22 of 30 patients (73.3%) with longer follow-up (median time of 10.3 months (IQR 6.3-18.2)). The relevance of the imaging methodology was reflected by its ability to assess individual lesions in cases of heterogeneous lesion responses, reveal the appearance of new lesions, and identify lesions that required specific consideration, such as targeted radiotherapy. CONCLUSIONS: Results of this retrospective analysis showed that biochemical responses to treatment and [68Ga]Ga-PSMA-11 PET/CT-based responses to treatment differ in one third of metastatic PCa patients. The latter additionally enabled lesion-based and not solely patient-based analysis. Monitoring response during treatment by [68Ga]Ga-PSMA-11 PET/CT is suitable for decision-making in patient management and choice of treatment in the majority of patients.
引用
- Kuten J, Sarid D, Yossepowitch O, et al. [68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res. 2019. PMID: 31468235. doi:10.1186/s13550-019-0554-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。